ClearNote Health Boosts Pancreatic Cancer Test Sensitivity to 82.6%
Event summary
- ClearNote Health's enhanced Avantect® Pancreatic Cancer Test now achieves 82.6% sensitivity and 97.5% specificity.
- Early-stage (I–II) detection sensitivity improved to over 76%.
- Test integrates epigenomic, genomic, glycan biomarkers with machine learning algorithms.
- Available through CAP/CLIA-certified lab in the U.S. and international partnerships in 70 countries.
- Being used in NHS's SAFE-D study and PRECEDE Consortium for pancreatic cancer detection.
The big picture
ClearNote Health's improved pancreatic cancer test addresses a critical gap in early detection, where conventional methods often fail. With pancreatic cancer projected to become the second leading cause of cancer deaths by 2030, this advancement could reshape precision oncology care. The test's integration into major studies like SAFE-D and PRECEDE positions it as a potential standard for high-risk patient screening.
What we're watching
- Clinical Adoption
- How quickly clinicians integrate the enhanced test into high-risk patient evaluations.
- Regulatory Pathway
- Whether ClearNote Health pursues FDA clearance to expand U.S. market access.
- Competitive Positioning
- The pace at which rivals match or exceed the test's detection performance metrics.
Related topics